The company has not filed an annual or quarterly report since its Q1 FY2020 10-Q, filed May 1, 2020. Its latest SEC filing is a 15-12B from May 18, 2020.
10-Q for Q1 FY2020, filed May 1, 2020
The sections below describe the company as of the FY2019 annual report.
Develops neoantigen-targeted T cell therapies and cancer vaccines for patients with cancer.
10-K for FY2019, filed Mar 2, 2020We have deep expertise in the development of neoantigen therapies, with both T cell and vaccine modalities. We are leveraging over a decade…View ↗
Our most advanced T cell program is NEO-PTC-01, our personal neoantigen adoptive T cell therapy, which consists of multiple T cell…View ↗
We are also advancing a T cell therapy program targeting shared neoantigens in genetically defined patient populations to direct the immune…View ↗
Finally, we also have two neoantigen vaccines in our portfolio, NEO-PV-01, a fully personal neoantigen cancer vaccine, custom-designed and…View ↗
10-Q for Q1 FY2020, filed May 1, 2020
−$16.6MView ↗
8-K, filed May 6, 2020
As described above in the Introductory Note to this Current Report on Form 8-K, on May 6, 2020, Neon completed the Merger pursuant to the…View ↗
Competes with Achilles Therapeutics, Adaptimmune Therapeutics, Adicet Bio, AgenTus Therapeutics, BioNTech, bluebird bio, Celgene, Genocea Biosciences, Gilead Sciences, Gritstone Oncology, Immatics Biotechnologies, IMV, Iovance Biotherapeutics, Lion TCR, Marker Therapeutics, Medigene, Neogene Therapeutics, Nouscom, PACT Pharma, and Regeneron Pharmaceuticals
10-K for FY2019, filed Mar 2, 2020Many of the companies against which we may compete have significantly greater financial resources and expertise than we do in research and…View ↗
Loading...
